Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetazolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 16/20 | 0.97 |
| ▸ | CA2 known ✓ | P00918 | 16/20 | 0.97 |
| ▸ | CA4 known ✓ | P22748 | 9/20 | 0.97 |
| ▸ | CA12 known ✓ | O43570 | 4/20 | 0.97 |
| ▸ | CA9 | Q16790 | 10/20 | 0.97 |
| ▸ | CA3 | P07451 | 4/20 | 0.97 |
| ▸ | CA6 | P23280 | 4/20 | 0.97 |
| ▸ | CA5A | P35218 | 4/20 | 0.97 |
| ▸ | CA7 | P43166 | 4/20 | 0.97 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.97 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.97 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CA11 | O75493 | 1/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetazolamide SCHEMBL11301585 | 1.00 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL2557036 | 0.98 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL23219 | 0.98 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL15513954 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL2845106 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL28346552 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL1998362 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL30094028 | 0.97 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL20553201 | 0.95 | CA1 (0.93) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL9390276 | 0.95 | CA1 (0.93) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113750055-B | Acetazolamide sodium freeze-dried powder injection and preparation method and application thereof | 苏州欧康维视生物科技有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-113750055-A | Acetazolamide sodium freeze-dried powder injection and preparation method and application thereof | 苏州欧康维视生物科技有限公司 | 2021-12-07 | — | — | CN | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-9511341-B2 | Method for preparing acetazolamide sodium powder | Sunny Pharmtech Inc. (TW) | 2016-12-06 | — | — | US | claimed |
| CN-103319436-B | The preparation of injection stage Vetamox (Am Cyanamid). and process for purification and lyophilized formulations thereof | 安徽省先锋制药有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-20150061169-A1 | METHOD FOR PREPARING ACETAZOLAMIDE SODIUM POWDER | SCI PHARMTECH, INC. (TW) | 2015-03-05 | — | — | US | claimed |
| CN-103319436-A | Preparation, refining method and freeze-drying preparation of injection-grade acetazolamide sodium | ANHUI PIOM PHARMACEUTICAL CO LTD | 2013-09-25 | — | — | CN | claimed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| CN-1079235-C | Acetazolamide microemulsion as eyedrops for treating glaucoma and its preparing process | OPHTHALMOLOGY INST HE NAN PROV (CN) | 2002-02-20 | — | — | CN | claimed |
| CN-1236614-A | Acetazolamide microemulsion as eyedrops for treating glaucoma and its preparing process | OPHTHALMOLOGY INST HENAN PROV (CN) | 1999-12-01 | — | — | CN | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CA1 1403/4885CA2 1000/4885CA4 849/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CA1 1105/4885CA2 1023/4885CA4 807/4885 |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | CA1 3302/4885CA2 2812/4885CA4 2737/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | CA1 3302/4885CA2 2812/4885CA4 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.